Search company, investor...

MicuRx Pharmaceuticals

Founded Year




Total Raised


Date of IPO


About MicuRx Pharmaceuticals

MicuRx(688373.SH) is a biopharmaceutical company whose mission is to discover and develop antibiotics with improved safety profiles to improve the treatment of resistant bacterial infections. The company was founded in 2007 and is based in Foster City, California.

Headquarters Location

950 Tower Lane Suite 390

Foster City, California, 94404,

United States


Missing: MicuRx Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: MicuRx Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing MicuRx Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

MicuRx Pharmaceuticals is included in 3 Expert Collections, including Game Changers 2018.


Game Changers 2018

36 items

Our selected startups are high-momentum companies pioneering technology with the potential to transform society and economies for the better.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

MicuRx Pharmaceuticals Patents

MicuRx Pharmaceuticals has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics




Antibiotics, Moraxellaceae, Bacterial diseases, Carboxylic acids, Inflammations


Application Date


Grant Date



Related Topics

Antibiotics, Moraxellaceae, Bacterial diseases, Carboxylic acids, Inflammations



Latest MicuRx Pharmaceuticals News

Legend Capital: The Logic of Technology Investment Has Changed

Sep 2, 2022

HONG KONG, Sept 2, 2022 - (ACN Newswire) - Legend Capital recently announced that it made its 100th IPO following the listing of its AI medical portfolio company Lunit on the KOSDAQ market on 21 July 2022. In addition, Legend Capital's CRO portfolio company R&G Pharmastudies was successfully listed on the ChiNext of Shenzhen Stock Exchange on 2 August 2022, while on 5 August 2022, the innovative drug portfolio company MicuRx Pharmaceuticals went public on the STAR Market, becoming the 101st IPO and the 102nd IPO in Legend Capital's investment portfolio. In a recent interview, Richard Li, President of Legend Capital, revealed the history of Legend Capital in technology investment and proposed that the logic of technology investment has undergone important changes. Over 100 IPOs and 100 Unicorns Legend Capital pays more attention to the quality rather than the quantity of IPOs, but the 100th IPO remarks an important milestone for Legend Capital. Richard Li, President of Legend Capital, said in the interview: "What matters is not about the quantity of IPOs, but more about the repeated verification of the investment expertise of Legend Capital team, who has long been rooted in technology investment. From Lunit to R&G Pharmastudies and MicuRx Pharmaceuticals, these IPO achievements at home and abroad are in line with Legend Capital's development: starting from the USD fund and growing stronger with the RMB fund. Among its peers, Legend Capital stands out with its distinctive feature - it is well-versed in the system of USD funds, but is also rooted in China and inherently adept at a local investment with the RMB fund. Looking back at Legend Capital's development history, we can see a microcosm of the changes in China's technology investment. In Richard Li's memory, since the company's investment in iFLYTEK in 2001, Legend Capital has been systematically investing in companies that are in the early stages of technological innovation, and many of them have become industry leaders such as iFLYTEK, Spreadtrum, CATL, WuXi AppTec, Pharmaron, Wuxi Lead Intelligent and CNGR Advanced Material, etc., tapping into core sectors of new energy, semiconductor, life science, new materials and so on. So far, among Legend Capital's invested companies, there are over 100 unicorn companies with a valuation of over USD1 billion, creating a huge and systematic technology investment footprint. With over two decades of expertise, Legend Capital has cultivated a profound understanding of the technology and innovation drives of China, accumulated rich resources around industries, and built a powerful portfolio ecosystem. Legend Capital helps overseas enterprises expand business in the Chinese market and promotes the global expansion of enterprises by bridging key resources in China such as R&D and supply chain. On the other hand, by leveraging its "China Insights", Legend Capital also helps portfolio companies and entrepreneurs in China to "go global" and achieve strategic objectives across the border by integrating overseas resources and opportunities, helping portfolio companies to respond to complex changes in the global industry landscape and meanwhile generating new investment opportunities. The Significance of 100 IPOs Looking back at the 100 IPOs, they are remarkably diverse while at the same time representing a consistent theme. Regarding the breakdown of listing location, 31 of our portfolio companies were successfully listed on Shenzhen Stock Exchange, 20 on Shanghai Stock Exchange, 22 on Hong Kong Stock Exchange, 1 on Taiwan Stock Exchange, 4 on New York Stock Exchange, 16 on Nasdaq, 5 on Korea Stock Exchange, 1 on Japan Exchange Group. With the majority listed on A-share markets, Legend Capital has extensive exit experience in multiple capital markets, which is relatively rare in investment institutions in China. From the market value (in RMB), there is 1 company with a market value of trillions - CATL; 10 companies with a market value of 100 billion, such as iFLYTEK, Pharmaron, WuXi AppTec, WuXi Biologics, Wuxi Lead Intelligent, Shanghai Putailai New Energy, CNGR Advanced Material, and JD Logistics; 15 companies with a market value of more than 50 billion, and 43 companies with a market value of more than 10 billion; and 25 of them are "little giants" companies with Specialization, Refinement, Differentiation & Innovation features. Legend Capital is active behind the rise of many Chinese technology companies. Richard Li summarized several characteristics regarding Legend Capital's 100 IPOs: First, it covers multiple sectors. The second is balance, which is also one of the deep impressions that Legend Capital has left on the public - internationalization practices in RMB funds and extremely strong localization capabilities in USD funds. Third, investment in technological innovation projects is the main focus, and investment in pure business model-innovation projects is relatively small. In addition, Legend Capital acts as the lead investor in most of its portfolio with a relatively large shareholding ratio, thus having board seats and could exert a certain influence on the operation of portfolio companies. Patience capital in industrial chain investment Founded in 2001, Legend Capital has experienced 20 years of technology iteration and innovation in China. "The founding team of Legend Capital all came from industrial rather than financial backgrounds, which determines the industrial and technology innovation genes of Legend Capital," Richard Li recalled. In China, Legend Capital is a pioneer in making technology investments using USD funds, much earlier than many of today's first-tier USD funds. Since 2015, Legend Capital has changed from a single fund investment business team to a unified platform to manage the operation of multiple funds, including long-term PE funds, TMT specialized funds, health care specialized funds, etc., to compose a more synergistic team. This synergy effect is reflected in Legend Capital's investment across different platforms and funds. With regard to its investment in the semiconductor industry, Legend Capital has systematic research on semiconductor companies and makes selective investments, with different funds investing in different types of targets. For example, Legend Capital invests in some enterprises that integrate resources and iterate products under a mature technology framework. Once successful, they will create a huge market of the replacement of the current framework, and even the first round of financing for these enterprises would reach billions of dollars. In the long run, they will grow into companies with a market value of hundreds of billions of dollars. Under such circumstances, Legend Capital will make a large proportion of investment through mature PE funds. However, the entire semiconductor industry is still in the early stage of development currently, and the latest semiconductor technology represents a new design concept and architecture, as well as a trend in cutting-edge technology. At this stage, many start-up technology companies need our support in the form of early-stage fund investment that accompanies their development in the long run. This will in turn contribute to the diversification, synergy and expansion of Legend Capital's investment tools and targets. The investment in the lithium battery industry, on the other hand, reflects the industry chain investment theme that is rooted in the industry background of the Legend Capital team. Benefiting from the long-term in-depth layout in the industrial mapping and the precise control of investment timing, Legend Capital has realized a number of landmark investments in the new energy field. Among them, projects such as Lead Intelligent, CATL, PUTAILAI, CNGR, Hymson have created huge returns for Legend Capital. Based on the prediction of the scale and trend of the downstream industry, Legend Capital has also systematically invested in assisted and autonomous driving along the direction of intelligent and unmanned new energy vehicles, as well as related sensor, radar, chip, and other projects in similar niches. Typical cases include, Zongmu Technology, MUNIU Tech, Black Sesame Technologies, etc. Richard Li said frankly: "Distinct from the internet sector, hard technology companies have a relatively long incubation period. Technology verification and productization need to be completed in the early stage, then put into the market, and then gradually scale up. The industry has large development potential and the enterprises have strong profitability. However, the market environment is complex, so it is hard for 'one winner to take all', and it is unrealistic to rely on first-mover advantage to achieve home runs. Therefore, investment institutions need to grasp the inflection point of the industry, such as when the effectiveness of the technology could be verified and when the product develops rapidly, which tests investors' judgment on timing. Richard Li summed it up in this way: To invest in science and technology, it is necessary to have an industrial mindset, sort out the industrial map, and then invest according to the timing of different stages and nodes of the industry. After that, we need to wait, and time will show us the answer. Investment institutions should have the patience and determination to accompany enterprises for a long time. The Logic of Technology Investment Has Changed Looking back on 20 years of experience in China's Venture Capital, Richard Li exclaimed that the industry is undergoing great changes today. "It's a systemic change including funding sources, investment directions and exit channels." He believes that these years are a critical turning point for the industry. Investment institutions need to make targeted adjustments to accommodate the new environment. In the past, the fundraising and exit of USD funds were both structured abroad, which led to most of the funds not actually investing in China. "To some extent, it is equivalent to going public in the United States with financial statements submitted from companies in China, and then selling shares in the United States market to exit." US dollar investors must now face up to the fact that the old game is over. Richard Li bluntly remarked that when USD funds began to shift investment focus from business model innovation to hard technology, in addition to the changes in target investment fields, the fundamental difference between the historic "two-end abroad" to invest in Chinese Concept Stocks and the new reality of China-rooted model of "investing onshore in China" put forth significant requirements for the localization of investment institutions, which requires long-term accumulation of resource networks and support from mid to back office. Besides, to be successful in using USD funds to invest in hard technologies in China with a focus on local listings and exits, it is very important to manage a complementary large-scale RMB fund as the cooperation between the two derives unique differentiation. Otherwise, we can only invest in individual "Cusp" projects opportunistically, rather than systematically investing in a long-term sustainable manner. This is also the challenge and opportunity that Legend Capital has always emphasized. Our latest plan focuses on technology investment, while paying attention to domestic A-share exit channels, we also take into account the exit channels for overseas investment projects in overseas capital markets, including Hong Kong stocks, US stocks, and capital markets such as South Korea and Japan. "Actually, these plans are things that we started doing a few years ago. If you just start to do these things today, I think it's too late." Said Richard Li. About Legend Capital Founded in 2001, Legend Capital is a leading VC&PE investor focusing on early-stage and growth-stage opportunities in China, with offices across Beijing, Shanghai, Shenzhen, Hong Kong, and Seoul, Korea. It currently manages USD and RMB funds of over US$10 billion in commitments and has invested in around 600 companies, covering technology, healthcare, consumer, enterprise service and intelligent manufacturing sectors. Rooted in China, Legend Capital participated in the rise of many world-leading companies through solid investment coverage and systematic post-investment value-add. Over the years, Legend Capital has also become a widely recognized name in bridging key resources in China and overseas through cross-border activities, and a valuable partner to Chinese and overseas investors. Legend Capital values long-term sustainable investment and incorporates ESG into its long-term development strategy. As a UNPRI signatory since November 2019, Legend Capital is among the first group of top VC/PE firms in China to join the initiative. For more information, please visit and follow us on LinkedIn @Legend Capital ( ). Topic: Press release summary

MicuRx Pharmaceuticals Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

MicuRx Pharmaceuticals Rank

MicuRx Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was MicuRx Pharmaceuticals founded?

    MicuRx Pharmaceuticals was founded in 2007.

  • Where is MicuRx Pharmaceuticals's headquarters?

    MicuRx Pharmaceuticals's headquarters is located at 950 Tower Lane, Foster City.

  • What is MicuRx Pharmaceuticals's latest funding round?

    MicuRx Pharmaceuticals's latest funding round is IPO.

  • How much did MicuRx Pharmaceuticals raise?

    MicuRx Pharmaceuticals raised a total of $268.25M.

  • Who are the investors of MicuRx Pharmaceuticals?

    Investors of MicuRx Pharmaceuticals include Legend Capital, China Merchants Securities Capital, Zhongtai Ventures, DT Capital Partners, Founder H Fund and 15 more.

  • Who are MicuRx Pharmaceuticals's competitors?

    Competitors of MicuRx Pharmaceuticals include Global Integrity, BioNano Genomics, Bioscience Vaccines, EpiTherapeutics, Aquapharm and 12 more.

Compare MicuRx Pharmaceuticals to Competitors

Carmot Therapeutics

Carmot Therapeutics is applying its technology, Chemotype Evolution, to address unmet chemical needs in drug discovery, focusing on high-profile targets for which drug leads have been difficult to identify. Carmot has built and optimized this platform to rapidly and efficiently unlock therapeutic target space not currently accessible to conventional small molecule technologies. Carmot is currently using Chemotype Evolution to discover novel drug candidates targeting validated pathways in metabolic disease, oncology, and inflammation. The company was founded in 2008 and is based in Berkeley, California.


NDRI aims to serve scientists with customized human biomaterials for use in studies to understand human disease and to develop drugs and therapies for treatments and cures. NDRI aims to make it easy for researchers to get the human tissues and organs they need, prepared, preserved and shipped precisely according to their specific scientific protocols.


Alzheimer's Disease is a modern curse that negates the many benefits from modern medicine and improved standards of hygiene and living. As the human population life-span is increased, a larger percentage of people will succumb to debilitating and distressing memory loss. Alzeim is dedicated to making available a natural plant alkaloid " Galanthamine (also widely called Galantamine) - that is proven to be a drug in the alleviation of memory-loss symptoms.nIt has few adverse side-effects and is currently extremely expensive to produce either from wild plants or by synthesis. By the application of research adding to its existing framework of knowledge, the company is establishing a new agri-industry in an upland region of Wales. Once production is adequate, it will make Galanthamine more widely available and affordable. Daffodils grown in the Black Mountains - helping Alzheimer's patientsnnGalanthamine has been known for some time as one of the few effective treatments for patients at certain stages of Alzheimer's Disease, having been produced in its natural form from plants found in the wild " principally in the Balkan region. This natural alkaloid is currently in short supply and because of the large number of potential patients (c. 700,000 currently in UK) is a very expensive treatment in total for a health provider to assume. In Scotland all patients who can benefit from it, and from related drugs, have access on prescription, but in England and Wales, the National Institute for Clinical Excellence (NICE) has decided to withdraw all anti-cholinesterase treatments from the National Health Service as regards new patients, because of the high total cost of branded medicines still subject to restrictive product licence. That decision has caused an outcry from sufferers and their families, and is being disputed in the High Court. It may not be resolved until after the drugs are able to be produced and sold in generic form. Nevertheless, global demand for Galanthamine is expanding rapidly. Alzeim expects to be able to provide much-needed extra quantities of the drug at lower prices thereby enabling many more patients to benefit from this treatment. Field trials, plant species and variety screening and laboratory extraction, purification and analysis work undertaken initially in co-operation with the IGER institute of University of Wales, Aberystwyth, indicated that a feasible route existed to produce Galanthamine economically in special regimes in parts of Mid-Wales. Since then, using mechanization under agronomic conditions, Alzeim has developed new production regimes with its own cultivars.nAmong other academic collaborations Alzeim is working on aspects of Galanthamine extraction and purification with the University of Manchester.

Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.

InterMed Discovery

InterMed Discovery is a Natural Product lead-discovery company, driving innovation through the generation of product candidates for the life science, food and cosmetics industries. Using a powerful validated Natural Product discovery engines, InterMed Discovery generates product pipelines of early stage pharmaceuticals and functional ingredients and also supports partners in research and lead generation.

ProtEra S.r.l.

The completion of the human genome sequence has created new and opportunities for the biotechnology industry to develop therapeutics. nnProtEra is a brilliant biotech company focused on the creation, development and distribution of target bio-molecules and new methods for the drug discovery. ProtEra was founded in 2003 by three scientists of the Magnetic Resonance Center (CERM) of the University of Florence. nProtEra's headquarter is based in the Scientific Campus of the University of Florence in Sesto Fiorentino. CERM, with its basket of technologies in post-genomic structural and computational biology, is "incubating" ProtEra during its initial phase. Before completing its full expansion, ProtEra accesses, through agreements with CERM, to high magnetic field NMR spectrometers equipped with high sensitivity probes (cryo-probes).

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.